C4 Therapeutics presented Phase 1 trial data showing cemsidomide in combination with dexamethasone achieved a 50% Overall Response Rate (ORR) at the highest dose level (100 µg) and a 40% ORR at the 75 µg dose level in heavily pretreated relapsed/refractory multiple myeloma patients. The median duration of response was 9.3 months, with no discontinuations related to cemsidomide. C4T plans to pursue accelerated approval in second-line and later patient populations, hosting a webcast for more information. The data supports cemsidomide as a potential class-leading IKZF1/3 degrader in the multiple myeloma treatment landscape. C4 Therapeutics announces positive Phase 1 trial results for cemsidomide in treating relapsed/refractory multiple myeloma. Patients achieved very good partial response and complete response rates, with up to 67% showing a positive response. Plans for two clinical trials are in progress for potential accelerated approvals, targeting highly refractory patients. Milestones include Phase 2 trial initiation in Q1 2026 and Phase 1b trial in Q2 2026. Cemsidomide shows promise in combination therapies, with a strong immunomodulatory effect and anti-myeloma activity. C4 Therapeutics will host an investor webcast today at 3 pm ET for further updates. C4 Therapeutics faces uncertainties in the development and commercialization of its product candidates, with risks including higher development costs and potential regulatory issues. The company highlights the importance of considering these factors when evaluating forward-looking statements. Investors can find more information in C4 Therapeutics’ recent SEC filings. The company does not plan to update this information unless required by law. For media inquiries, contact Loraine Spreen, Senior Director of Corporate Communications & Patient Advocacy.
Read more at 1. “Tesla surpasses $1 trillion market value after strong earnings report.” – CNBC
2. “Amazon reports record-breaking holiday sales, exceeding $150 billion.” – Reuters
3. “CDC recommends Pfizer or Moderna vaccines over J&J due to blood clot risks.” – Wall Street Journal: C4 Therapeutics Presents Cemsidomide Phase 1 Multiple